Heron

Heron Therapeutics is a commercial-stage biotechnology company focused on acute care and oncology supportive-care products. The company markets approved therapies for chemotherapy-induced nausea and vomiting, postoperative nausea and vomiting, and postoperative pain, including CINVANTI, SUSTOL, APONVIE, and ZYNRELEF. Heron’s approach combines patented drug-delivery technologies with well-characterized pharmacology to develop differentiated formulations intended to improve efficacy, convenience, and duration of effect. The company’s business is centered primarily on commercialization in the United States, with ZYNRELEF also approved in Canada and multiple European countries. Heron is publicly traded on Nasdaq under the symbol HRTX and operates from Cary, North Carolina.